Six months to the day that the World Health Organization (WHO) declared it a public health emergency, the SARS-CoV-2 virus, with its hideous red spikes, continues to taunt the world, hopping from host to host and haunting humans, many of whom wonder the same thing: What’s next?
By filing an IND with the FDA to initiate a phase II/III study of EB-05, a monoclonal antibody, Edesa Biotech Inc. joined the handful of companies developing COVID-19 treatments that inhibit Toll-like receptor 4 (TLR4) signaling. The Toronto-based company’s stock (NASDAQ:EDSA) responded by rocketing 81.38% upward Thursday to close at $9.45, after trading as high as $19.10.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Affinity, Altum, American Gene Technologies, Appili, Betterlife, Cerevel, FSD, Gen1e, Inovio, Johnson & Johnson, Neurotrope, Nichi-Iko, Pharvaris, PDL, Takeda, Teva, Worldwide Clinical Trials.
Senhwa Biosciences Inc., of Taipei, Taiwan, said casein kinase 2 (CK2) is the right target to aim at when developing a COVID-19 therapeutic treatment. The company’s silmitasertib is the only clinical-stage inhibitor of CK2, a kinase recently identified by researchers as being hijacked by SARS-CoV-2.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Emmaus, Inovio, Melt, Merck, Novartis, Regulus, Relief, Ridgeback, Roche, Scynexis, Teva.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Auris, Constant, Denali, Dimerix, Genentech, Krystal, Repare, Samus, Sanofi.
RSS
